Friday, February 2, 2018

Dear Colleagues:
We are excited to invite you to attend the Canadian Breast Cancer Symposium at Whistler, BC February 2 and 3, 2018. As in previous years the Symposium’s
objective is to provide state of the art information to optimally manage our breast cancer patients. Another focus for this
Canadian meeting is to increase communication and collaboration among breast cancer treaters nationwide.
Molecular Biology Session
Update on Molecular Subtypes and Their Clinical Meaning
Role of Molecular Assays in Clinical Practice
POG Results on 200 Breast Cancer Patients : Local Experience
Neo/Adjuvant Session
A Paradigm Shift: Avoiding Breast Surgery in Breast Cancer
What Next if Significant Residual Disease after Neo-adjuvant Treatment?
New Agents for Breast Cancer in Neo-adjuvant Setting
Update on Adjuvant Treatment of Breast Cancer
5 Highlights from SABCS 2017
Role of CD4/6 Inhibitors in Metastatic Breast Cancer
Role of Checkpoint Inhibitors in Metastatic Breast Cancer
Focus on Biosimilars in Breast Cancer
Management of Toxicities from Therapies in Breast Cancer
EBCC will once again take place in the context of very tangible advances made for patients in prevention, diagnosis, treatment, survivorship, and advances
firmly based again
driven by research in recent years, emphasising the successful application of a multidisciplinary approach. This latest edition is
on an all-inclusive vision of breast cancer and brings together clinicians, scientists, patient
representatives and health professionals of diverse profiles to tackle key issues facing patients
throughout the continuum of the breast cancer journey. The programme will highlight the importance of teamwork
and interactions between all professionals and specialities involved in breast cancer. We are also pleased
EBCC11 will take account of the very successful ‘Multidisciplinary Teams in the Real World’.
Main themes:

 New therapeutic strategies of endocrine dependent tumours

 Deciphering the immunotherapy landscape in breast cancer
 DNA repair and epigenetics in breast cancer
 Innovative clinical trial methodology to bring to the clinic faster biomarkers and technology
 Applying liquid biopsies to breast cancer clinical care
 The level of evidence for genomic alterations in breast cancer
SESSION 1
Supportive Issues and Special Populations
Breast Cancer in African Americans
Lymphedema Management

Diagnosing and Managing Skin Toxicity

SESSION 2
Breast Pathology for the Non-Pathologist
Phyllodes Tumors in 2018
The New AJCC Staging System: Rationale and Clinical Application
The Immune Tumor Microenvironment in Breast Carcinomas: Pathologic Evaluation and Significance

SESSION 4
Subtype-Specific Treatment

All Triple Negative Cancers Are Not Created Equal

Biologic Studies of Triple Negative Cancer

Biologic Studies of Triple Negative Cancer

SESSION 5
Issues in Young Women with Breast Cancer
Imaging Strategies in Dense Breasts
Management of Pregnancy-Associated Breast Cancer
Contralateral Prophylactic Mastectomy

Optimal Adjuvant Therapy in Young Women

How Much of a Risk Factor for Local-Regional Recurrence is Young Age?
Management of Locoregional Recurrence
The Cleveland Clinic Comprehensive Breast Cancer Program presents the 2018 Cleveland Breast Cancer Summit: Collaborating For A Cure, a live
educational multi-disciplinary summit focusing on up-to-date reviews of advances in management strategies for patients with breast cancer and comorbidities.

Localization Techniques in the Axilla

Florescence Guided Sentinel Lymph Node Procedures

Smart Glasses for Breast Surgery

Axillary Reverse Mapping

Lymphovenous Bypass for Prevention of Lymphedema

Triple Mapping Technique

Assessment of Lymphedema

Pain Management in the Axilla and Abdominal Donor Site

Strategies for Axillary Seroma Prevention

Change in to Scrubs
MORNING LAB – ADVANCED AXILLARY SURGERY TECHNIQUES
LUNCH
Management of Atypical Lesions
Percutaneous Tumor Removal (IPEX)
Tumor Ultrasound Guided Incision (TUGI) Mastectomy

Intraoperative Image Guided Margin Assessment

Prepectoral Breast Reconstruction

Nerve Sparing Mastectomy and its Sensory Recovery Reconstruction

Pain Free Mastectomy

Prevention and Management of Complex Breast Wounds

Fat Grafting
Clinical Implications of Fat Grafting in a Cancer Patient
CHARTER 1: DUCTAL CARCINOMA IN SITU
-Avoiding overtreatment of DCIS
-How wide a margin do we need for DCIS?
-Should radiotherapy be routinely recommended after wide local excision of DCIS?
-Does immediate breast reconstruction delay the delivery of adjuvant treatment: The iBRA-2 prospective multicentre cohort study
The Breast Reconstruction Research Collaborative

INDUSTRY SYMPOSIUM: AMGEN

From past paradigms to future frontiers: Exploring the role of bone modifying agents in breast cancer
-Therapeutic targeting of bone metastasis – from advanced disease to early dissemination
-Bisphosphonates in breast cancer: Past, present and future

INDUSTRY SYMPOSIUM: ROCHE

The role of immunotherapy in breast cancer
-The application of immuno-oncology to breast cancer – where are we?
-What can we learn from the immuno-oncology experience in other tumour types?

CHARTER 1: IMAGE ANALYSIS FOR SCIENTISTS AND PATHOLOGISTS

-Applying digital pathology to translational breast cancer research
-Imaging-based analysis of ErbB/HER signaling dimer and immunoregulatory molecules – from preclinical science to biomarker discovery
-Deciphering spatial heterogeneity of tumour immune response
-Clinicopathological significance of heterogeneity of tumour infiltrating lymphocytes in invasive breast cancer

EXCHANGE AUDITORIUM: SELECTED FREE COMMUNICATIONS

- Peri‐operative aromatase inhibitor treatment in determining or predicting long-term outcome in early breast cancer – the POETIC Trial
- Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration
significantly reduces breast cancer recurrence and mortality: an EBCTCG meta-analysis of 34,123 women in 25 randomised trials
- Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer
treated with 5 years of endocrine therapy
- Impact of a BRCA germline mutation on survival – Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH)

CHARTER 2 & 3: COSTS OF TREATMENT

-From price to value: Keeping breast cancer care affordable
-Critically examining the true value of our therapies: The only way to meaningful gains in breast cancer

CHARTER 1: TRIPLE NEGATIVE BREAST CANCER

-The biology of new targets
-Precision medicine for triple negative breast cancer patients using a systems biology approach
Immunologic advances